Amcor R&D increased by 15.8% to $44.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 63.0%, from $27.00M to $44.00M. Over 4 years (FY 2021 to FY 2025), R&D shows an upward trend with a 4.7% CAGR.
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
research_and_development| Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $26.00M | $25.00M | $23.00M | $24.00M | $24.00M | $25.00M | $24.00M | $27.00M | $25.00M | $27.00M | $28.00M | $25.00M | $26.00M | $28.00M | $27.00M | $27.00M | $38.00M | $46.00M | $38.00M | $44.00M |
| QoQ Change | — | -3.8% | -8.0% | +4.3% | +0.0% | +4.2% | -4.0% | +12.5% | -7.4% | +8.0% | +3.7% | -10.7% | +4.0% | +7.7% | -3.6% | +0.0% | +40.7% | +21.1% | -17.4% | +15.8% |
| YoY Change | — | — | — | — | -7.7% | +0.0% | +4.3% | +12.5% | +4.2% | +8.0% | +16.7% | -7.4% | +4.0% | +3.7% | -3.6% | +8.0% | +46.2% | +64.3% | +40.7% | +63.0% |